NSE: LAURUSLABS · 6 October 2026
- Laurus Labs Limited shares advanced 3.99% on Tuesday, closing at ₹2,050.00 after moving between an intraday low of ₹1,958.40 and a high of ₹2,053.10.
- Laurus Labs announced its financial results for the quarter ended June 30, 2026, reporting a 29% year-on-year increase in revenue to ₹2,026 crore. EBITDA surged 66% to ₹644 crore with margins expanding to 31.8%, driven by strong commercial momentum in CDMO and affordable medicines divisions.
- Trading volume was 1.38 times the 20-day average daily volume.
Why is Laurus Labs share price rising on 6 October 2026?
Laurus Labs Limited shares advanced 3.99% on Tuesday, closing at ₹2,050.00 after moving between an intraday low of ₹1,958.40 and a high of ₹2,053.10.
The stock outperformed broader market benchmarks during the session. The Nifty index posted a gain of 0.98%, while the thematic Nifty Pharma sector benchmark rose 1.66%, indicating stronger relative momentum in Laurus Labs compared to its broader pharmaceutical peers.
While no single new corporate announcement was released today, the broader market context follows the company's active strategic developments, including its recently outlined expansion plans and robust Q1 financial performance reported in late July 2026, where revenue reached ₹2,026 crore and EBITDA stood at ₹644 crore.
21.78 lakh shares traded by 6 October 2026 · 03:15 PM IST. This compares with a 20-day average daily volume of 15.73 lakh shares (1.38 times). The five-day average daily volume was 13.33 lakh shares. Separately, the NSE report for 5 October 2026 showed 6.38 lakh shares delivered, representing 46.42% of that day’s traded volume. The same report recorded 63,463 trades.
The stock moved higher with above-average volume, outpacing both the broader Nifty index and the Nifty Pharma sector benchmark. In the absence of a same-day catalyst, the price action aligns with sustained buying interest and positive sentiment in pharmaceutical equities.
Latest Company Developments
Laurus Labs announced its financial results for the quarter ended June 30, 2026, reporting a 29% year-on-year increase in revenue to ₹2,026 crore. EBITDA surged 66% to ₹644 crore with margins expanding to 31.8%, driven by strong commercial momentum in CDMO and affordable medicines divisions.
Demonstrates strong operational performance and scaling capabilities across core business segments.
The company released an updated investor presentation outlining its long-term growth strategy, specialized modalities including cell and gene therapy, peptides, and antibody-drug conjugates (ADCs). Management detailed accelerated capital expenditure plans exceeding ₹3,000 crore slated across FY27 and FY28.
Provides visibility into future capacity expansion and diversification into high-value biotechnology segments.
The company provided an update on its composite scheme of arrangement involving its wholly-owned subsidiaries Laurus Synthesis Private Limited and Sriam Labs Private Limited, noting the NCLT scheduled the next hearing for September 10, 2026.
Highlights ongoing internal corporate restructuring aimed at streamlining business operations and specialized units.
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Laurus Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 10.15% on 30 June 2026. This compares with 11.22% on 31 March 2026, a change of -1.07 percentage points.
The filing reported 38 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Execution of ongoing capital expenditure programs across API, fermentation, and advanced biologics
- Progress on the NCLT composite scheme of arrangement and corporate restructuring
- Volume and delivery participation trends relative to the 20-day average volume
- Subsequent quarterly financial performance and CDMO order book updates
More Laurus Labs news and dated analysis →
Frequently Asked Questions
What is the latest Laurus Labs company news?
Laurus Labs announced its financial results for the quarter ended June 30, 2026, reporting a 29% year-on-year increase in revenue to ₹2,026 crore. EBITDA surged 66% to ₹644 crore with margins expanding to 31.8%, driven by strong commercial momentum in CDMO and affordable medicines divisions.
How strong was Laurus Labs’s trading volume?
21.78 lakh shares traded, 1.38 times the 20-day average daily volume. The price and volume data are dated 6 October 2026 · 03:15 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 June 2026. Quarterly holdings do not identify purchases made on the article date.
Article by: WittyTrades Research Desk
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.